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The investigation of a pleural effusion is, in general, a very straight forward process with the
combination of clinical history, examination, radiology and pleural fluid analysis leading to
diagnosis in most cases. While most fluid samples are sent for routine analysis including
protein, LDH, glucose, cytology and microbiology, there are a number of more unusual fluid
analyses available which in some cases directly lead to, and in others are suggestive of the
diagnosis. Moreover, other fluid markers are constantly being evaluated as a diagnostic tool.
In this review, we describe these non-routine pleural fluid analyses in detail. English language
publications in MEDLINE and references from relevant articles from January 1 1990 to August 1
2009 were reviewed. Keywords searched in combination were pleural fluid, effusion, analysis,
transudate, exudate and diagnosis.
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The first step in the analysis of pleural fluid is to determine
whether the effusion is a transudate or an exudate. The
second is to analyse fluid further to identify the most likely
aetiology.Pleuralfluidsamplesaregenerally sent for a routine
set of analyses. However, a variety of additional analyses are
available when clinical suspicion warrants their use (e.g.,
chylothorax). Moreover, despite the fact that Light’s Criteria
remain the gold standard in differentiating exudate from
transudate, there are occasions when these criteria will mis-
class an effusion such as in case of cardiac failure treatedwith
diuretic therapy. Here we discuss many of the additional non-
routine tests available in the diagnosis of pleural effusion as
well as those that are currently being evaluated (Table 1).
Adenosine deaminase
Adenosine deaminase (ADA) is a predominant T-cell
enzyme involved in converting adenosine to inosine and
deoxyadenosine to deoxyinosine. Pleural fluid ADA levels
>40 U/l strongly suggest tuberculosis (TB) in areas of high
prevalence whereas low ADA levels have a high negative
predictive value in areas of both high and low prevalence.1
The higher the ADA level in these cases the greater the
chance of TB. Importantly, ADA measurements are sensitive
in HIV patients despite a lower CD4þ lymphocyte count.2
Liang et al. demonstrated that in cases of TB, ADA had
a sensitivity of 92% and a specificity of 90% in their meta-
analysis of 63 studies incorporating 2796 patients.3 Speci-
ficity is increased in cases of lymphocytic exudates.1reviations
adenosine deaminase
brain natriuretic peptide
25 cancer antigen 125
5-3 carbohydrate antigen 15-3
þ cluster of differentiation 4
carcinoembryonic antigen
-10 culture filtrate protein 10
complement component 3/4
C4 cleavage fragment
C-reactive protein
RA 21-1 cytokeratin 19 fragment
-6 early secretory antigen 6
high density lipoprotein
interferon-g-release assay
b interleukin-1 betaNontuberculous lymphocyte predominant pleural effu-
sion rarely has an ADA level greater than 40 U/l. This was
highlighted when 18 patients out of 630 from a total of 3
series had an ADA level above the cut-off, due to either
infection or malignancy.1,4e6
The main non-TB related cause of an elevated ADA is
empyema. Approximately two thirds of empyema cases and
one third of parapneumonic effusions have a raised ADA
although these conditions have a very different cell
differential with TB being predominantly lymphocytic and
parapneumonic effusion/empyema being predominantly
neutrophilic.1 Pleural fluid ADA >40 U/l has also been
described in cases of malignancy (in particular lymphoma),
rheumatoid arthritis, systemic lupus erythematosis and
infections such as brucellosis and Q fever.7,8
ADA has a number of isoenzymes with ADA 1 raised in
conditions such as empyema, malignancy and inflammatory
disorders and ADA 2 raised in tuberculous pleural effu-
sions.9 The discriminatory benefit of analysing ADA isoen-
zymes has not been put in to practice as yet.
Cholesterol/triglyceride
Cholesterol and triglyceride levels are extremely useful in
the diagnosis of chylothorax and pseudochylothorax.
Cholesterol <200 mg/dl with a triglyceride level >110 mg/
dl is diagnostic of chylothorax whereas cholesterol
>200 mg/dl with a triglyceride level <50 mg/dl is found in
pseudochylothorax.10 These criteria were originally intro-
duced by Staats et al. who noted that pleural fluid with
a triglyceride of >110 mg/dl had a 1% chance of being non
chylous.11 The demonstration of chylomicrons in the pleuralIL-6 interleukin-6
LBP lipopolysaccharide binding protein
LDL low density lipoprotein
LDH lactate dehydrogenase
NT-proBNP N-terminal prohormone brain natriuretic
peptide
SC5b-9 soluble terminal complement complex
PCT procalcitonin
PNH paroxysmal nocturnal haemoglobinuria
SLE systemic lupus erythematosis
sFasL soluble FAS ligand
sTREM-1 soluble triggering receptor expressed on
myeloid cells-1
TB tuberculosis
TNF-a tumour necrosis factor alpha
VATS video assisted thoracoscopic surgery
WBC white blood cells
Table 1 The potential diagnostic use of non-routine fluid markers in the diagnosis of pleural effusion.
Pleural fluid marker Potential diagnostic use
Adenosine deaminase/interferon-g Tuberculous effusion
Amylase Pancreatitis or oesophageal rupture
Antinuclear antibody Systemic lupus erythematosis
Cholesterol/triglyceride Chylothorax or pseudochylothorax
Transudate vs exudate
Complement
C3/C4 Rheumatoid arthritis, SLE, cardiac failure
SC5b-9 Tuberculous effusion
Creatinine Urinothorax
Haematocrit Haemothorax
NT-proBNP Cardiac failure
Rheumatoid factor Rheumatoid arthritis
Tumour markers
CA 125 Ovarian carcinoma
CEA Adenocarcinoma
CA 15-3 Metastatic breast carcinoma
CYFRA 21-1 Squamous cell carcinoma
Mesothelin Malignant mesothelioma
Miscellaneous
Bilirubin/Glycosoaminoglycans Transudate vs exudate
C-reactive protein Parapneumonic effusion
PCR Mycobacterium tuberculosis/Strep. pneumoniae
TNF-a/IL-1b/IL-6/sFASL Tuberculous effusion
Il-8 Complicated vs uncomplicated parapneumonic effusion
sTREM-1/LBP Infectious pleural effusion
Hyaluronon Malignant mesothelioma
1094 E.E. McGrath et al.fluid using lipoprotein analysis is the gold standard test for
the diagnosis of chylothorax but this facility is not routinely
available in all centres. It certainly is recommended in
borderline fluid cholesterol/triglyceride levels.10
Pleural cholesterol analysis has also been used in the
classification of exudates and transudates. Hamm et al.
examined the pleural fluid in a series of patients and found
that an optimal cut-off for the correct differentiation of the
effusions was 60 mg/dl. Using this cut-off they found that 5%
of cases were incorrectly classified.12 Yilmaz et al. analysed
the pleural fluid in 255 patients and found that using a cut-off
of 60 mg/dl had an accuracy rate of 95.7% with a sensitivity
and specificity of 95.3% and 96.2% respectively.13
Fluid triglyceride and cholesterol use in chylothorax/
pseudochylothorax is well established, however, it may also
have a role in the correct identification of misclassified
effusions, although further research is warranted before it
becomes routinely used.
Interferon-g
Interferon-g is a cytokine that like ADA is released from
CD4þ lymphocytes. Its role is to increase the bactericidal
function of macrophages and it was originally found in
elevated concentrations in the pleural fluid from TB
patients.1 A meta-analysis performed by Jiang et al. in 2007
revealed that this cytokine has a sensitivity of 89% and
a specificity of 97% when diagnosing TB.14 When interferon-
g and ADA are used together a joint sensitivity and speci-
ficity of 96% for interferon-g and 93% for ADA is achieved.15Elevated Interferon-g levels can also be found in pleural
fluid in cases of malignancy and empyema.16 As ADA is
widely analysed in high TB prevalent areas, interferon-g
measurements have not been used all that often, however
interferon-g-release assays (IGRAs) are becoming more
popular as an alternative to the tuberculin skin test for the
detection of latent TB.17 These assays measure interferon-g
release from sensitised T cells either in the pleural fluid or
peripheral blood. The T cells become sensitised in response
to antigens such as culture filtrate protein 10 (CFP-10) and
early secretory antigen 6 (ESAT-6) which are both Myco-
bacterium tuberculosis specific.1
Reported sensitivity of this assay has been variable with
Baba et al. and Ariga et al. reporting a sensitivity of 45% and
95% respectively when used on mononuclear cells from
pleural fluid.2,18 Losi et al. demonstrated a specificity of
76%.19 The role of commercial IGRAs such as QuantiFERON-
TB Gold and T-SPOT.TB in the diagnosis of pleural effusion is
controversial due to the limited amount of data collection
and product evaluation in clinical studies.
Clearly the current use of interferon-g is hampered by
the superiority of ADA in tuberculous effusion, while the
data on IGRAs is controversial. Further research and
consensus is awaited.
NT-proBNP
Cardiac failure is themost commoncauseofpleural effusion.20
While fluid analysis typically reveals a transudate, there are
situations where this may not be the case. For example,
Pleural fluid analysis 1095cardiac failure patients who have recently commenced
diuretic therapy may have effusions that are in the exudative
range. Bartter et al. postulated that this was due to water
leaving the pleural space faster than the lactate dehydroge-
nase (LDH) and protein.21 Clearly, the use of Light’s Criteria in
this situation will result in a patient being diagnosed with an
exudative effusion with an increased chance of referral for
more invasive procedures to aid diagnosis.
Brain natriuretic peptide (BNP) in serum and pleural fluid
have been of benefit in assisting with the diagnosis of cardiac
failure related effusions. It is a neurohormone that is secreted
from the ventricle walls in response to increased volume and
pressure. As the myocytes are stretched, preproBNP is
released and is quickly cleaved to BNP and NT-proBNP.22
Physiologically, BNP inhibits the renineangiotensin system
and increases diuresis, naturesis and vasodilation.23
Serum BNP has been used in the diagnosis of heart
failure with one large study in patients with acute dyspnoea
demonstrating its ability to distinguish cardiac failure from
pulmonary related dyspnoea with accuracy, having a high
negative predictive value.24 It has also proven useful in
determining the prognoses in cardiac failure and acute
coronary artery disease, monitoring treatment response
and diagnosing early left ventricle dysfunction.25
While NT-proBNP monitoring in blood has been used to
diagnose cardiac failure and monitor treatment response,
recent studies have demonstrated a use for this test in
pleural fluid analysis particularly in cases of suspected
cardiac failure where traditional methods have not been
sufficient (e.g., Light’s Criteria).23,26,27 Pleural fluid NT-
proBNP has good diagnostic accuracy, sensitivity and spec-
ificity in differentiating cardiac from non cardiac related
effusions.25 The main issue with this test is deciding on an
appropriate cut-off level between cardiac and non cardiac
disease. All the published studies so far have used
a different cut-off level and therefore more work is
required to reach a consensus. Traditionally, in suspected
cardiac related effusions that have been described as
exudate using Light’s Criteria (15%), the next test usually
recommended and performed is to measure the serum-fluid
albumin gradient.25,28 Roth et al. demonstrated that 75% of
cases misclassified using Light’s Criteria were classified
correctly using the serum-fluid albumin gradient.28 Seyhan
et al. recently showed that the albumin gradient correctly
classified 70% of their cases misclassified using Light’s
Criteria but that using serum or pleural fluid NT-proBNP was
superior to the use of Light’s Criteria  albumin gradient in
the diagnosis of cardiac failure related effusions.25
Importantly, Nt-proBNP may be raised in the elderly and
in patients with renal failure.29
Without doubt more studies are required to gain
consensus on cut-off levels and also to evaluate the role of
NT-proBNP in other transudative effusions. While Light’s
Criteria remain the gold standard there may be a role for
NT-proBNP analysis in cases of exudative effusion where
clinical suspicion points towards cardiac failure.Tumour markers
The role of pleural fluid tumour markers in malignant
effusion has been evaluated. CA 125 is produced by ovariantumours but is also produced by mesothelial cells. This can
often result in higher levels of CA 125 in pleural fluid when
compared with serum, in cases of ovarian malignancy.30 CA
125 levels in pleural fluid can also be raised in squamous
and adenocarcinomatous malignant pleural effusions where
it may have prognostic relevance.31
CEA is expressed on mucosal cells but is overexpressed in
the case of malignant disease particularly adenocarci-
noma.32 Tomita et al. in their series of 150 patients, found
that elevated pleural lavage CEA levels in patients with
adenocarcinoma undergoing thoracotomy was associated
with a poorer prognosis.33 Galbis-Caravajal et al demon-
strated a median survival of 9.7 months when pleural
lavage CEA levels were >0.3 hg/mL compared with
a median survival of 23.9 months when levels were lower
than this.34 Bielsa et al. had similar results demonstrating
a median survival of 5.1 months in patients with metastatic
adenocarcinoma whose pleural fluid CEA levels were
>100 hg/mL compared with a median survival of 9 months
in patients with CEA levels lower than this.31
CA 15-3 has been used for the detection and monitoring
of metastatic breast cancer.35 High correlation between
serum and fluid levels of the tumour marker has been
demonstrated.36 It has also been shown to differentiate
benign from malignant effusions especially when combined
with other tumour markers.37,38
CYFRA 21-1 (cytokeratin 19 fragments) is a cytokeratin
tumour marker found on epithelial and mesothelial cells. It
has been shown to have a diagnostic role in squamous cell
carcinoma and a prognostic role in non-small cell lung
cancer where increased levels were associated with
a poorer outcome.30,36
Mesothelin is a cell surface glycoprotein involved in cell
adhesion and signalling which can be cleaved from the cell
surface creating a soluble form which is also known as
soluble mesothelin related protein (SMR). Mesothelin is
expressed by normal mesothelial cells but is overexpressed
in some cancers including mesothelioma.39 Mesothelin is
a highly specific, moderately sensitive tumour marker
which was originally found in increased levels in the serum
of 84% of patients with established mesothelioma compared
with 2% of patients with other cancers, lung disease or
pleural disease.40 Further research performed by Scher-
pereel et al. reported similar findings in a study in 2006.41
More recently, Creaney et al. evaluated the use of
pleural fluid mesothelin in the diagnosis of mesothelioma in
192 patients and found significantly higher levels of meso-
thelin in effusions of patients with mesothelioma (speci-
ficity 98%, sensitivity 67%) compared with effusions of non-
neoplastic origin.42
In 7 out of 10 cases mesothelin levels were raised in the
effusion collected 3 weeks to 10 months before the diagnosis
of mesothelioma was made and in 4 out of 8 of these, meso-
thelin levels were increased in the effusion but not in the
serum.42 The authors concluded that elevated pleural fluid
levels of mesothelin may indicate the need for invasive
investigationat anearly stage, facilitating a speedier diagnosis
leading to less patient anxiety and earlier intervention.43
The use of pleural fluid tumour markers is not recom-
mended solely for the diagnosis of pleural effusion and at
best the use of a panel of tumour markers might be useful
in deciding on further invasive investigation.44 Porcel et al.
1096 E.E. McGrath et al.examined 416 patients with pleural effusions and found
that at least one tumour marker from a panel including
CEA, CA 125, CA 15-3 and CYFRA 21-1, was elevated in only
54% of malignant effusions. A negative result obviously did
not exclude a malignant diagnosis.45 Further work by Bielsa
et al. has now highlighted the use of a tumour marker panel
in analysing prognosis with a combination of CA 125 and
CYFRA 21-1 useful in adenocarcinoma and various combi-
nations of CEA, CA 125, and CYFRA 21-1 useful in squamous
cancer of the lung.31
As studies on the use of pleural fluid tumour markers are
relatively rare, their regular use in malignant effusions is
not recommended. Further research in this area is neces-
sary to ascertain whether or not they will provide any
definite clinical benefit.
Amylase
Amylase is an enzyme which breaks down complex carbo-
hydrates into simple sugars. Serum levels are typically
elevated in pancreatitis but also in mumps, perforated
viscus (peptic ulcer, oesophageal rupture), cholecystitis,
cystic fibrosis, cancer, tubal pregnancy and alcoholism.
Amylase in pleural fluid is high if it exceeds the upper limit
of normal for serum or if the fluid-serum ratio >1.46
Villena et al. found that the most common causes for
amylase rich pleural effusions are cancer (majority), TB,
pancreatitis, pancreatic pseudocyst and liver cirrhosis.47
Rarer causes include cardiac failure, parapneumonic effu-
sion, ruptured ectopic pregnancy and trauma. Villena et al.
also noted that the highest amylase levels correlated with
a shorter median survival in patient with malignancy.47 This
echoed earlier findings in a study by Foresti et al. (1994),
who demonstrated high pleural fluid amylase concentra-
tions and an elevated pleural/serum amylase ratio in
malignant pleural effusions particularly in those related to
adenocarcinoma.48 Overall, 10% of malignant effusions
have a raised amylase.49
However, despite its diagnostic strength, Branca et al.
concluded that routinely testing pleural fluid for amylase
does not assist in determining the origin of the effusion. In
their study on 379 patients, they demonstrated that it was
not cost effective to routinely measure amylase in pleural
fluid nor was it clinically indicated, only being recom-
mended if the pre-test probability of pancreatic disease or
oesophageal rupture was high.50
Amylase isoenzyme analysis is useful in cases of suspected
oesophageal rupture where salivary amylase is raised.51
Raised salivary amylase where oesophageal rupture is not
suspected ismost commonly found inmalignancy. Pancreatic
disease related effusions usually have raised pancreatic
amylase.52
The measurement of amylase isoenzymes is well
described in the diagnosis of pancreatic or oesophageal
rupture related effusion. Amylase measurement in the
investigation of malignancy is not routinely recommended.
Complement
The complement system comprises of over 30 proteins,
forming an essential part of human innate immunity. Its mainroles are in cell lysis, opsonisation, chemotaxis and inflam-
mation. Increased serum complement activity is found in
cancer and certain infections whilst decreased activity is
seen in cirrhosis, glomerulonephritis, systemic lupus eryth-
ematosis (SLE), paroxysmal nocturnal haemoglobinuria
(PNH), hereditary angioedema and malnutrition.53
Despite the fact that several studies have highlighted
complement activation in the pleural fluid of patients with
rheumatoid arthritis, SLE and tuberculosis,54,55 the routine
analysis of complement (C3, C4) in rheumatoid arthritis and
SLE is not recommended due to low specificity and the fact
that serum rheumatoid factor (RF) and antinuclear anti-
body (ANA) are more sensitive and specific.7
The measurement of complement activation products
has also been analysed. Research on SC5b-9, a product
formed by the binding of S protein to C5b-9 complexes at
the C5b-7 stage of assembly in consequence of complement
activation, has found that this product is elevated in the
pleural fluid of patients with tuberculous effusions unlike
malignant and transudative effusions.54,56 In particular
Hara et al. demonstrated that all tuberculous effusions in
their study had SC5b-9 levels >2 mg/L, with malignant
effusions <2 mg/L.54 Using 2 mg/L as the cut-off they
reported a sensitivity of 100% with a specificity of 79% (also
raised in rheumatoid, parapneumonic and some treated
malignant effusions) and found a positive correlation
between pleural fluid ADA and SC5b-9. Hidaka et al. (1995)
also found SC5b-9 was significantly higher in tuberculous
compared to malignant effusions.57 In a similar vein, Porcel
et al. found pleural SC5b-9 was useful in differentiating
tuberculous from malignant pleural effusions, but C3a-
desArg (complement activation product) was not.58
Salomaa et al. (1998) found that SC5b-9 levels were
>2 AU/L in rheumatoid arthritis related effusion and were
<2 AU/L in malignant effusions. Fluid C3 and C4 levels were
also significantly lower along with an increased C4d/C4
ratio in the rheumatoid patients when compared with
malignant and tuberculous effusions.56 The use of SC5b-9 is
hampered by the superior diagnostic accuracy of ADA in
tuberculous effusions and the fact that rheumatoid related
effusions are extremely rare with serum rheumatoid factor
analysis being preferred.56
More recently, Shitrit et al. found pleural C4 levels were
low in cardiac failure related effusions and that therefore
not surprisingly complement levels correlated with fluid
total protein and amylase levels.59 They also found that
normal complement levels of C3 and C4 virtually exclude
cardiac failure as an aetiological factor. They advocate the
use of pleural fluid complement in the evaluation of effu-
sions when traditional assessment methods fail.59
Currently, the use of pleural fluid complement is not of
benefit in the investigation of inflammatory disease as
serum markers such as RF or ANA are as effective and easier
to perform. Their use in other forms of effusion such as
those related to cardiac failure requires further research
and evaluation.
Antinuclear antibody/rheumatoid factor
While finding lupus erythematosis cells in pleural fluid is
diagnostic of SLE related effusion, much work has also
involved the analysis of pleural fluid ANA.60
Pleural fluid analysis 1097Porcel et al. have highlighted that measuring ANA in
pleural fluid provides no additional diagnostic information
above that achieved with serum analysis. They also believe
that in patients with SLE and a pleural effusion of unknown
cause, the absence of ANA or other autoantibodies such as
anti-double stranded DNA (dsDNA) or extractable nuclear
antigen (ENA) from pleural fluid argue against the diagnosis
of lupus pleuritis.61 Wang et al. also found in their study
that a negative ANA test in pleural fluid made the diagnosis
of lupus pleuritis unlikely. However, they felt that high
titres of ANA in a pleural effusion of unknown aetiology
should warrant a search for malignant disease.62
Pleural fluid rheumatoid factor titres can be measured
and are often >1:320.10 It is rarely performed as it has
a low specificity and like fluid ANA often mirrors the serum
value, adding little to the investigation.53
The presence of rheumatoid arthritis cells or ‘‘ragocytes’’
(WBC with phagocytic intracellular inclusions) in the pleural
fluid has been described in rheumatoid related effusions and
furtherwork has revealed that their presence correlateswith
the usual biochemical findings in the pleural fluid of rheu-
matoid patients.63 Testing for ragocytes is generally not
recommended as they have a low specificity.64
Creatinine/haematocrit
Creatinine measurement is a useful tool in the diagnosis of
urinothorax, a rare complication due to kidney obstruction.
The fluid is typically a transudate (urine odour) with a low
pH but a pleural fluid creatinine to serum creatinine ratio of
>1 is diagnostic.10 The fluid moves through the retro-
peritoneum to the pleural space on the same side as the
renal obstruction.65
A ratio of pleural fluid to serum haematocrit 0.5 is
indicative of a pleural haemorrhage (haemothorax) that
requires urgent drainage.10 This test is particularly useful
in differentiating blood stained effusions from actual
haemorrhage.
Miscellaneous
A number of other analyses have been described in the
literature although their use as yet has not been put in to
regular practice. We describe some of these here.
Previous research on fluid bilirubin revealed a ratio of
fluid to serum bilirubin >0.6 indicates an exudate with
a sensitivity of 90.6% and a specificity of 96.2%.13
Polymerase chain reaction (PCR) analysis of pleural fluid
may be used when infection is suspected (e.g., Strepto-
coccus pneumoniae or TB). It has a detection rate of 40e
80% for M. tuberculosis in pleural fluid although detection
rates are lower in culture negative cases.66,67
Studies measuring IL-1b and IL-6 demonstrated that they
were increased in plasma and tuberculous pleural fluid,
indicating an inflammatory status.68 Alexandrakis et al. also
measured IL-1b in pleural effusions but they considered the
test too impractical and costly.69
Kiropoulos et al. studied acute phase markers such as
CRP, IL-6 and TNF-a in the pleural fluid of 124 patients with
inflammatory and malignant disorders. Pleural fluid CRP
was higher in parapneumonic effusions when comparedwith tuberculous and malignant effusions registering 100%
sensitivity for a cut-off value of 5.3 mg/dL. IL-6 was higher
in both parapneumonic and tuberculous compared with
malignant effusions.70 This was not completely in keeping
with previous studies where despite a similar finding of
higher IL-6 in tuberculous compared with malignant effu-
sions, lower levels of IL-6 in parapneumonic compared to
tuberculous effusions were described.71,72
TNF-a has also been found in higher concentrations in
tuberculous rather than malignant effusions in keeping with
previous studies, with 96.0% sensitivity and 93.0% speci-
ficity for a cut-off value of 88.1 pg/mL.70,73 The same study
reported that fluid levels of IL-6 and TNF-a were higher in
the fluid than in serum indicating local production whereas
CRP levels were lower in fluid than in the serum indicating
a systemic inflammatory response. Kiropoulos et al.
proposed that the markers might provide useful results in
the differentiation of infectious from malignant effusions
although further studies were recommended.70 Porcel et al.
recently measured IL-8 concentration in the pleural fluid of
100 patients and found that using a cut-off of 1000 rg/mL,
IL-8 differentiated complicated from uncomplicated para-
pneumonic effusion with a sensitivity of 84% and a speci-
ficity of 82%.74 They also found that measuring CRP with
a cut-off of 80 mg/L had a sensitivity of 72% and a speci-
ficity of 71% when it came to differentiating the two.74 Even
more recently the same authors investigated pleural fluid
sTREM-1 (soluble triggering receptor expressed on myeloid
cells-1), PCT (procalcitonin), LBP (lipopolysaccharide
binding protein) and CRP (C-reactive protein) in stored fluid
samples from 308 patients and concluded that all but PCT
had a value in identifying patients with infectious effusions
particularly complicated parapneumonic effusions.75
Porcel et al. have also analysed the contribution of
a pleural antigen assay to the diagnosis of pneumonia. Using
a rapid immunochromatographic test on effusions from 140
patients, they concluded that this test improved the stan-
dard diagnostic methods of pleural fluid and blood cultures
even post antibiotic consumption and enhanced the urinary
antigen assay.76
Budak et al. measured sFASL (soluble FAS ligand) levels
in the pleural fluid from 35 patients and found that this
marker was significantly higher in tuberculous than in
malignant and parapneumonic effusions. They propose that
this marker may be useful in identifying this condition.77
A recent pilot study evaluated the use of measuring
glycosoaminoglycans in pleural fluid.78 The authors found
that using an appropriate cut-off level, these markers could
help differentiate exudates from transudates and benign
from malignant disease.
Elevated pleural fluid hyaluronan concentrations have
been described in malignant mesothelioma and in certain
non-malignant conditions especially rheumatoid arthritis
although there has been very little further published on this
compound.79Conclusion
While standard pleural fluid analysis is generally sufficient
to narrow the differential or diagnose most pleural effu-
sions, a number of other techniques are available in
1098 E.E. McGrath et al.difficult or obscure cases. Moreover, newer fluid analysis
techniques are continuously emerging that with further
research and time may significantly improve the arsenal of
techniques available to the physician.Conflict of interest statement
We have no financial or conflict of interest.
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